Ácidos graxos poli‐insaturados ômega‐3 e lúpus eritematoso sistêmico: o que sabemos?

Borges, Mariane; Santos, Fabiana de Miranda Moura dos; Telles, Rosa Weiss; Correia, María Isabel Toulson Davisson; Lanna, Cristina Costa Duarte

doi:10.1016/j.rbr.2013.12.002

Cited by 17 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Starting late 1980s, more than 10 interventional studies with omega-3 PUFAs as treatments have been done in patients with SLE. Some studies showed promising results, especially for SLE patients with cardiovascular disease, which has emerged as an important cause of death in patients with SLE ( 99 , 100 ).…”

Section: Environmental Factors and Slementioning

confidence: 99%

SLE: Another Autoimmune Disorder Influenced by Microbes and Diet?

2015

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease. Despite years of study, the etiology of SLE is still unclear. Both genetic and environmental factors have been implicated in the disease mechanisms. In the past decade, a growing body of evidence has indicated an important role of gut microbes in the development of autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and multiple sclerosis. However, such knowledge on SLE is little, though we have already known that environmental factors can trigger the development of lupus. Several recent studies have suggested that alterations of the gut microbial composition may be correlated with SLE disease manifestations, while the exact roles of either symbiotic or pathogenic microbes in this disease remain to be explored. Elucidation of the roles of gut microbes – as well as the roles of diet that can modulate the composition of gut microbes – in SLE will shed light on how this autoimmune disorder develops, and provide opportunities for improved biomarkers of the disease and the potential to probe new therapies. In this review, we aim to compile the available evidence on the contributions of diet and gut microbes to SLE occurrence and pathogenesis.

show abstract

Section: Environmental Factors and Slementioning

confidence: 99%

SLE: Another Autoimmune Disorder Influenced by Microbes and Diet?

2015

View full text Add to dashboard Cite

show abstract

“…46 Specifically, omega-3 PUFAs (ie, EPA and DHA) can reduce biomarkers of inflammation such as C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). [47][48][49] Thus, they exert antiinflammatory action in renal diseases, improve their morbidity, and delay their progression, as was reported by some authors. 17 Some authors suggest that omega-3 PUFAs physiologically reduce blood TG levels but do not significantly alter LDL-C and HDL-C levels.…”

Section: Omega-3 Pufas and Their Potential Therapeutic Role In Nephromentioning

confidence: 62%

<p>The Supportive Treatment of IgA Nephropathy and Idiopathic Nephrotic Syndrome: How Useful are Omega-3 Polyunsaturated Fatty Acids?</p>

Uwaezuoke¹,

Muoneke²,

Mbanefo³

2020

IJNRD

View full text Add to dashboard Cite

IgA nephropathy (IgAN) is the most prevalent glomerular disease in young adults worldwide, while idiopathic nephrotic syndrome (INS) represents the most frequent manifestation of glomerular disease in childhood. Over the years, studies have speculated about the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) in improving morbidity in both forms of chronic kidney disease (CKD). The proposed mechanisms of action include reduction of proteinuria and modulation of dyslipidemia. Although in vitro and in vivo experimental studies report the suppressive effect of omega-3 PUFAs on inflammatory pathways linked with the progression of nephropathy, the evidence supporting their beneficial effect in IgAN and INS is still weak. Also, their ability to regulate levels of total cholesterol, low-density lipoprotein-cholesterol (LDL-C), and triglycerides (TG) suggests that they could delay both dyslipidemia-associated nephrotoxicity and atherosclerosis. Most of the clinical trials that were conducted on their therapeutic benefits in IgAN patients reported positive outcomes with low and high doses of omega-3 PUFAs. However, few of the trials noted inconclusive findings, with low-quality evidence suggesting potential improvements in surrogate renal function outcomes. If the beneficial effect of omega-3 PUFAs is predicated on their hypolipidemic action, much higher doses could be used in welldesigned randomized-controlled trials (RCTs) to determine if they could produce better renal function outcomes and provide much stronger evidence of their therapeutic benefits in IgAN and INS. However, the current hypothetical mechanisms of action in these forms of CKD also include the effect of omega-3 PUFAs on renal inflammatory pathways and glomerular proteinuria. Perhaps, the unresolved therapeutic efficacy of these fatty acids in IgAN and INS suggests that their exact mechanisms of action are yet to be fully established. In this narrative review, we aim to appraise the current evidence of their potential therapeutic benefits in these diseases.

show abstract

“…Several clinical trials have reported beneficial effects of increased omega-3-fatty acids in coronary artery disease, 56,57 obesity, 58 and rheumatic disorders. 59–61…”

Section: Fish Oil (Omega-3 Fatty Acids)mentioning

confidence: 99%

“…Several clinical trials have reported beneficial effects of increased omega-3-fatty acids in coronary artery disease, 56,57 obesity, 58 and rheumatic disorders. [59][60][61] Clinical data in IBD A large meta-analysis looked at the impact of dietary intake of fish and omega-3-fatty acids and risk of IBD. 62 This included 10 studies with a total sample size of 282,610, of which 2002 had IBD (1061 with Crohn's disease and 937 with UC).…”

Section: Pathophysiologymentioning

confidence: 99%

Complementary and alternative medications in the management of inflammatory bowel disease

Picardo

Altuwaijri

Devlin

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

The use of complementary and alternative medications (CAM), products, and therapies not considered to be part of conventional medicine is common among patients with inflammatory bowel disease (IBD). Patients often turn to these therapies as they are considered natural and safe, with significant benefit reported beyond disease control. There is emerging evidence that some of these therapies may have anti-inflammatory activity; however, robust evidence for their efficacy in modulating disease activity is currently lacking. Patients often avoid discussing the use of CAM with their physicians, which may lead to drug interactions and/or reduced adherence with conventional therapy. It is important for physicians to be aware of the commonly used CAM and current evidence behind these therapies in order to better counsel their patients about their use in the management of IBD. This narrative review provides an overview of the evidence of the more commonly used CAM in patients with IBD.

show abstract

Ácidos graxos poli‐insaturados ômega‐3 e lúpus eritematoso sistêmico: o que sabemos?

Cited by 17 publications

References 50 publications

SLE: Another Autoimmune Disorder Influenced by Microbes and Diet?

SLE: Another Autoimmune Disorder Influenced by Microbes and Diet?

<p>The Supportive Treatment of IgA Nephropathy and Idiopathic Nephrotic Syndrome: How Useful are Omega-3 Polyunsaturated Fatty Acids?</p>

Complementary and alternative medications in the management of inflammatory bowel disease

Contact Info

Product

Resources

About